Atrium Therapeutics, Inc. (RNA)
NASDAQ:RNA
RNA Stock Chart & Stats
$13.23
-$0.39(-1.27%)
At close: 4:00 PM EST
$13.23
-$0.39(-1.27%)
Day’s Range― - ―
52-Week Range$11.95 - $16.77
Previous CloseN/A
Volume185.29K
Average Volume (3M)2.09M
Market Cap
N/A
Enterprise Value$1.99B
Total Cash (Recent Filing)$1.70B
Total Debt (Recent Filing)$94.56M
Price to Earnings (P/E)―
Beta-16.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,114,391
10 Day Avg. Volume2,820,857
30 Day Avg. Volume2,094,181
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)5.88
Price to Sales (P/S)529.62
P/FCF Ratio-14.96
Enterprise Value/Market Cap10.00T>
Enterprise Value/Revenue106.14
Enterprise Value/Gross Profit-16.47
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$25.00Price Target Upside88.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Collaboration Revenue DiversificationCollaboration revenues from research partnerships with major pharmaceutical firms contribute to non-dilutive funding and validate external interest in the technology platform.
M&A Deal ProgressAcquisition by Novartis is moving forward with a planned shareholder vote and expected regulatory approvals, supporting a clear path toward deal completion.
SpinCo Capitalization And LeadershipPlanned SpinCo will be capitalized with $270 million in cash and led by the company's Chief Program Officer, providing immediate funding and experienced leadership for independent development.
Bears Say
Analyst Risk DesignationAnalyst's Neutral rating with a High Risk designation highlights limited upside expectations and deal-related uncertainty that could pressure the stock.
Reduced Ownership In Cardiology AssetsAtrium's sole ownership of precision cardiology applications reduces the company's stake in cardiology programs and may limit future upside from those assets.
Atrium Therapeutics, Inc. News
RNA FAQ
What was Atrium Therapeutics, Inc.’s price range in the past 12 months?
Atrium Therapeutics, Inc. lowest stock price was $11.95 and its highest was $16.77 in the past 12 months.
What is Atrium Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Atrium Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Atrium Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Atrium Therapeutics, Inc. overvalued?
According to Wall Street analysts Atrium Therapeutics, Inc.’s price is currently Undervalued.
Does Atrium Therapeutics, Inc. pay dividends?
Atrium Therapeutics, Inc. does not currently pay dividends.
What is Atrium Therapeutics, Inc.’s EPS estimate?
Atrium Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atrium Therapeutics, Inc. have?
Atrium Therapeutics, Inc. has 17,114,391 shares outstanding.
What happened to Atrium Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atrium Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
RNA Stock 12 Month Forecast
Average Price Target
$25.00
▲(88.96% Upside)
Technical Analysis
Ownership Overview
―
Insiders
― Other Institutional Investors
95.19% Public Companies and
Individual Investors